Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-06-13 Earnings Release
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2023, by Rafael Holdings, Inc. It specifically references Item 2.02, which relates to "Results of Operations and Financial Condition." The text states that the company distributed an earnings release announcing results for the fiscal quarter ended April 30, 2023, and that the earnings release is furnished as Exhibit 99.1. The document itself is a current report providing an update on quarterly financial results, not the full quarterly report or detailed financial statements. The length is 4743 characters, which is relatively short and consistent with a Form 8-K earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER).
2023-06-13 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events that shareholders should know about. The content describes a Securities Purchase Agreement involving the purchase of shares and warrants, amendments to a Registration Rights Agreement, and board appointment details. This is an update on financing activity and capital structure changes. The document is not a full financial report, earnings release, or management discussion, but rather a specific event disclosure related to capital transactions. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4627 characters, which is consistent with a detailed 8-K filing rather than a brief announcement or a full annual/interim report.
2023-06-05 English
SCHEDULE 13D
Major Shareholding Notification
2023-05-11 English
Director's Dealing 2023
Director's Dealing
2023-05-08 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the approval of a stock repurchase program and strategic investment plans. It includes a press release as an exhibit and does not contain detailed financial statements or comprehensive financial analysis. The document is relatively short (4644 characters) and serves as an announcement of corporate actions rather than a full financial report. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock repurchase programs.
2023-04-04 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.